Nanomedicine Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Nanomedicine stocks.

Nanomedicine Stocks Recent News

Date Stock Title
Nov 21 AZN AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
Nov 21 AZN We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
Nov 21 AZN 3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
Nov 21 AZN AstraZeneca upgraded to Neutral from Sell at UBS
Nov 21 AZN AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg
Nov 20 AZN AstraZeneca raised to neutral at UBS despite China headwinds
Nov 20 AZN AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
Nov 20 AZN Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
Nov 20 AZN AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades
Nov 20 AZN FTSE 100 and European-listed stocks to own in 2025, according to Barclays
Nov 19 AZN CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
Nov 19 AZN AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC
Nov 19 AZN CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
Nov 18 AZN GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Nov 18 AZN AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership
Nov 18 AZN Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Nov 18 AZN Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now?
Nov 18 AZN Is AstraZeneca PLC (AZN) A Cheap NASDAQ Stock To Invest In Now?
Nov 15 AZN How analysts are reacting to RFK Jr. as Trump's HHS pick
Nov 15 AZN Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
Nanomedicine

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials (materials whose structure is on the scale of nanometers, i.e. billionths of a meter).Functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. The size of nanomaterials is similar to that of most biological molecules and structures; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical research and applications. Thus far, the integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug delivery vehicles.
Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices in the near future. The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging. Nanomedicine research is receiving funding from the US National Institutes of Health Common Fund program, supporting four nanomedicine development centers.Nanomedicine sales reached $16 billion in 2015, with a minimum of $3.8 billion in nanotechnology R&D being invested every year. Global funding for emerging nanotechnology increased by 45% per year in recent years, with product sales exceeding $1 trillion in 2013. As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.

Browse All Tags